We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Flow Cytometry Detects Myelodysplasia in Peripheral Blood

By LabMedica International staff writers
Posted on 27 Mar 2018
Myelodysplastic Syndromes (MDS) are a group of myeloid neoplasms characterized by inefficient hematopoiesis, peripheral blood (PB) cytopenias and high risk of leukemic progression.

The diagnosis of MDS is essentially based on morphological and cytogenetic abnormalities, such as the presence of cytopenias, blasts in the PB and/or bone marrow (BM), and dysplasia in one or more hematopoietic cell lineages. More...
Although PB cytomorphological findings provide information to suspect of MDS, only BM studies are presently accepted to confirm the diagnosis.

Scientists associated with the Hospital de Santo António Porto (Porto, Portugal) studied 14 patients with low-risk MDS (LR-MDS), eight males and six females, with a median age of 76 years, ranging from 66 to 88 years and that had at least one appointment at the hospital from September 2015 to November 2015. An equal number of healthy blood donor controls were studied in parallel, eight males and six females, with a median age of 55 years, ranging 19 to 63 years.

Clinical and laboratory data were retrospectively collected from the hospital records. Bone marrow (BM) aspirate samples were used to prepare BM smears. These were stained with Leishman’s stain, and cell morphology was analyzed by conventional light microscopy. Cytogenetics studies were performed on BM aspirates, either by conventional cytogenetics and/or fluorescence in situ hybridization (FISH).

Peripheral blood samples were collected into ethylene-diamine-tetra-acetic acid tripotassium salt containing tubes and processed within 24 hours after collection. Cell immunophenotyping was performed by 8-color flow cytometry (FCM) using fluorochrome-conjugated monoclonal antibodies (mAbs) with different specificities. Sample acquisition was performed in a BD FACSCanto II flow cytometer.

The team found that peripheral blood neutrophils from patients with LR-MDS frequently had low forward scatter (FSC) and side scatter (SSC) values and low levels of CD11b, CD11c, CD10, CD16, CD13 and CD45 expression, in that order, as compared to normal neutrophils. In addition, patients with LR-MDS commonly display a higher fraction of CD14+CD56+ and a lower fraction of CD14+CD16+ monocytes in the PB. The immunophenotyping score based on which PB samples from patients with LR-MDS could be distinguished from normal PB samples with a sensitivity of 93% and a specificity of 100%.

The authors concluded that their pilot study revealed an altered neutrophil immunophenotype, often accompanied by an abnormal monocyte immunophenotype, in the PB from nearly all LR-MDS cases, and suggest that assessment of abnormal antigen expression in PB mature myeloid cells may help to identify patients with LR-MDS. Once translated into a straightforward FCM-based score and converted into a visual analogue scale, MDS thermometer, these findings can be easily applied in clinical practice. The study was published on March 13, 2018, in the journal BMC Hematology.

Related Links:
Hospital de Santo António Porto


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.